Up on promising interim data from cancer treatment study

NuCana

15/01/2021 13:48

** Shares of drug developer  NCNA.O  rise 6.1% to $6.90
premarket 
    ** Co reports promising interim data at 2021 ASCO
Gastrointestinal Cancers Symposium from ongoing three-part study
of its experimental drug, NUC-3373, in patients with colorectal
cancer  urn:newsml:reuters.com:*:nGNE4D84TG
    ** Ten patients out of 37, who received NUC-3373 either as
monotherapy or in combination with leucovorin, showed disease
stabilization and longer duration of progression-free survival;
five patients experienced tumor shrinkage - NCNA
    ** Co said NUC-3373 also achieved 62% disease control rate  
 
    ** Stock up 44.7% this year, as of Thursday's close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))